AbbVie to Acquire TeneoOne and Lead Asset for Multiple Myeloma Treatment June 25, 2021 Auto Bot News 0 AbbVie has exercised its right to acquire TeneoOne, along with its lead immunotherapeutic asset for the potential treatment of multiple myeloma.
